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Abstract 
Background: Epidemiological evidence has associated Alzheimer’s disease (AD) with 
vascular risk factors (VRFs), but whether treatment of VRFs reduces the incidence of 
dementia and AD is uncertain.  
Objective: To conduct a systematic review and meta-analysis to summarize available data on 
the impact of treatment of VRFs on dementia and AD incidence.  
Methods: Pertinent studies published until 1 January 2018 were identified from PubMed. 
Both randomized controlled trials (RCT) and prospective studies that investigated the impact 
of treatment of VRFs on dementia or AD incidence were included.  
Results: Eight RCTs and 52 prospective studies were identified. Antihypertensive treatment 
was associated with a nonsignificant reduced risk of dementia in RCTs (n=5; relative risk 
[RR], 0.84; 95% confidence interval [CI], 0.69–1.02) and prospective studies (n=3; RR, 0.77; 
95% CI, 0.58–1.01) and with reduced AD risk in prospective studies (n=5; RR = 0.78; 95% 
CI, 0.66–0.91). In prospective studies, treatment of hyperlipidemia with statins, but not 
nonstatin lipid-lowering agents, was associated with reduced risk of dementia (n=17; RR, 
0.77; 95% CI, 0.63–0.95) and AD (n=13; RR, 0.86; 95% CI, 0.80–0.92). The single RCT on 
statins and dementia incidence showed no association. Data from one RCT and six 
prospective studies did not support a beneficial impact of antidiabetic drugs or insulin therapy 
on dementia risk.  
Conclusion: Current evidence indicates that antihypertensives and statins might reduce the 
incidence of dementia and AD. Further trials to determine the effect of VRF on AD are 
needed.   
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INTRODUCTION  
Dementia is a growing public health concern because of the globally ageing population 
and the lack of effective treatments. By 2050, the number of people with dementia worldwide 
may nearly triple, from 46.8 million to a projected 131.5 million [1]. The major form of 
dementia is Alzheimer’s disease (AD), accounting for about 60% or more of all cases [2].  
Chief pathological hallmarks of the AD brain are neurofibrillary tangles and abnormal 
accumulation of amyloid-β (Aβ) peptides in amyloid plaques [3]. Recent clinical trials in AD, 
many based on the amyloid hypothesis, have been disappointing [4] and this has increased 
interest in other potential therapeutic avenues. Considerable evidence indicates that vascular 
risk factors (VRFs) [2, 3, 5] are linked to AD. Observational studies have found that 
modifiable VRFs, including hypertension, hypercholesterolemia, and obesity in midlife, 
type 2 diabetes mellitus, physical inactivity, and smoking are associated with an increased 
risk of AD [2, 3, 5-7]. It was recently estimated that a third of all AD cases worldwide might 
be attributable to potentially modifiable risk factors [6]. This suggests that treatment of VRFs 
might reduce the incidence of AD, but whether treating VRF does indeed reduce the risk of 
AD is unclear. 
Previous reviews have summarized the evidence from randomized controlled trials 
(RCTs) or observational studies assessing the effect of hypertension [8-10] or hyperlipidemia 
[11-14] treatment on dementia risk. However, to the best of our knowledge, there are no 
systematic reviews summarizing all available evidence from both RCTs and prospective 
studies on all major VRFs in relation to incidence of AD and all-cause dementia. We 
therefore performed a contemporary systematic review and meta-analyses to summarize 
available data from RCTs and prospective observational studies investigating the influence of 
treatment of established VRFs (hypertension, hyperlipidemia, and type 2 diabetes mellitus) or 
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smoking cessation, exercise, or weight loss intervention on the incidence of AD and all-cause 
dementia. 
 
METHODS  
Search Strategy 
This systematic review and meta-analysis followed the PRISMA guidelines [15]. PubMed 
was searched, without restrictions, from inception until 1 January 2018. The predefined key 
words used for the database search are described in Table S1. The reference lists of relevant 
publications were scrutinized to identify further studies.  
 
Selection criteria 
Articles were included if they met the following inclusion criteria: 1) randomized 
controlled trial (RCT) or prospective study (including register-based cohorts); 2) assessed 
treatment of an established VRF with available drug treatment (i.e., hypertension, 
hyperlipidemia, or type 2 diabetes mellitus) or smoking cessation, exercise, or weight loss 
intervention; 3) the outcome was all-cause dementia or AD; and 4) a relative risk (RR) 
estimate with corresponding 95% confidence interval (CI) or sufficient data to calculate these 
were provided. Exclusion criteria were cross-sectional study; case-control study; 
nonrandomized trial; and animal study. Where duplicate publications were available, the 
study with the longest follow-up or largest number of participants was included.  
 
Data extraction and quality assessment 
The following information was extracted from each study: first author’s last name, year of 
publication, name of the study or database used, country in which the study was performed, 
outcome(s) assessed and diagnostic criteria, total number of participants and cases, age of 
participants, mean follow-up time, type of treatment, variables adjusted for in full model, and 
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the most fully adjusted RR with corresponding 95% CI. Assessment of study quality (ranging 
from 0 to 9) was performed using the Newcastle-Ottawa Scale [16]. Details of how the 
criteria were applied are shown in Figure S1.  
 
Statistical analysis 
Where results for a treatment-outcome association were reported by two or more studies, 
results were combined in a meta-analysis, using a random-effects model [17]. Between-study 
heterogeneity was assessed with the I2 statistic [18]. The following interpretation for the I2 
values were used: <30% = no or low heterogeneity; 30%–75% = moderate heterogeneity; and 
>75% = notable heterogeneity. Meta-regression and subgroup analyses were carried out if 
feasible (≥2 studies per stratum) to assess potential sources of heterogeneity by study quality 
(quality score 0–7 [low quality] vs 8–9 [high quality]), duration of follow-up (<5 vs ≥5 years), 
and number of cases (<200 vs ≥200). Publication bias was evaluated with Egger’s test [19]. 
All statistical analyses were carried out using Stata, version 14.2 (StataCorp, College Station, 
TX). We considered p-values <0.05 to be statistically significant. 
 
RESULTS 
 
Literature search 
A total of 7136 articles of which 60 met the inclusion criteria were identified (Figure S2). 
The eligible studies comprised 8 RCTs and 52 articles based on prospective studies (Table 1).  
 
Randomized controlled trials  
A striking feature was the paucity of data from RCTs with only 8 studies in total, 
including five on antihypertensive treatment, one each on hyperlipidemia and type 2 diabetes 
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mellitus treatment, and one that assessed the effectiveness of a multifactorial VRF 
intervention.  
 
Hypertension treatment 
Four of the five RCTs [20-24] found a reduction in dementia incidence in patients 
randomized to antihypertensive treatment [20, 21, 23, 24] but results reached statistical 
significance in only one trial [21] (Table S2). In a meta-analysis of these RCTs (total of 
22 016 patients and 936 cases) the combined RR of dementia for active treatment vs placebo 
was 0.84 (95% CI, 0.69–1.02), with moderate heterogeneity between trials (Figure 1). In a 
sensitivity analysis in which one trial at the time was omitted and the rest analyzed to assess 
the influence of single trials on the overall results, the RRs ranged from 0.79 (95% CI, 0.64–
0.98) when the Study on Cognition and Prognosis in the Elderly trial [22] was excluded to 
0.90 (95% CI, 0.78–1.03) when the Systolic Hypertension in Europe Study [21] was 
excluded. There was no evidence of significant publication bias. 
 
Hyperlipidemia treatment 
The single RCT assessing the influence of hyperlipidemia treatment on dementia 
incidence was the Heart Protection Study [25]. In this trial, 20 536 UK adults, 40–80 years of 
age, with non-fasting total cholesterol concentrations of at least 3.5 mmol/L (135 mg/dL) and 
a history of coronary heart disease, other occlusive arterial disease, or diabetes mellitus were 
randomly allocated to receive simvastatin or matching placebo. The average difference in 
low-density lipoprotein cholesterol concentration during a mean follow-up of 5 years was 1.2 
mmol/L. Patients assigned to simvastatin had statistically significantly reduced all-cause and 
coronary mortality but the number of incident dementia cases during follow-up was similar in 
both groups (0.3%; n = 31 cases). 
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Type 2 diabetes mellitus treatment 
One RCT evaluated the efficacy of intensive glucose control on vascular outcomes in 
11 140 type 2 diabetes mellitus patients [26]. The mean glycated hemoglobin concentration 
was lower in the intensive-control group (6.5%) than in the standard-control group (7.3%) 
after a median 5 years of follow-up. Intensive glucose control reduced the incidence of 
combined major macrovascular and microvascular events but not dementia (n = 109 cases) 
[26]. 
 
Multifactorial VRF intervention 
One RCT has examined whether more intensive treatment of VRFs in patients with first 
ever stroke or transient ischemic attack influences poststroke cognitive functioning or risk of 
dementia (secondary outcome) [27]. Pharmacological intervention included antiplatelet agents 
or warfarin, antihypertensives, statins, antidiabetic drugs, and vitamin B complex including 
folic acid. Patients were also offered smoking cessation courses and were encouraged to 
perform regular moderate physical activity, to consume a diet rich in fruit, vegetables, fish, 
and low-fat dairy products, and less sugar, and not to use alcohol excessively. Patients were 
randomized either to the intervention group (n = 98) or the control group (n = 97) that 
received care as usual. One-year poststroke, 11 (13%) patients in the intervention group and 
17 (19%) in the control group had developed dementia (p = 0.30) [27]. 
 
Prospective observational studies 
Among the prospective studies, results on hypertension, hyperlipidemia, and type 2 
diabetes mellitus treatment were reported in respectively 20, 27, and seven studies (two 
studies reported results on two treatments).  
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Hypertension treatment 
Thirteen prospective studies [28-40] were included in the meta-analysis of hypertension 
treatment and dementia or AD risk (Table S3). The combined RRs for any antihypertensive 
medication use vs nonuse were 0.77 (95% CI, 0.58–1.02) for dementia, with moderate 
heterogeneity among studies, and 0.78 (95% CI, 0.66–0.91) for AD, with low heterogeneity 
(Figure 2). In two studies that reported results on duration of use of antihypertensive drugs in 
relation to risk of dementia or AD, the inverse association was more pronounced with longer 
use [32, 36]. Of the different classes of antihypertensive drugs, angiotensin receptor blockers, 
calcium channel blockers, and diuretics were statistically significantly inversely associated 
with risk of dementia and AD (Figure 2). There was no evidence of publication bias. 
Seven studies compared different classes of antihypertensive drugs and risk of dementia 
or AD [41-47] (Table S4). Among three studies that compared angiotensin-converting 
enzyme inhibitors with other antihypertensive drugs, one study observed a stronger inverse 
association with angiotensin-converting enzyme inhibitors [44], whereas the other two studies 
found no clear difference [41, 42]. Angiotensin receptor blockers seemed to be more strongly 
inversely related to risk of dementia or AD than angiotensin-converting enzyme inhibitors or 
other antihypertensive drugs in three [43, 44, 46] out of four studies [43-46]. One study found 
that use of calcium-channel blockers was associated with reduced risk of dementia and AD 
[47].   
 
Hyperlipidemia treatment 
A total of 27 studies were included in the meta-analysis of hyperlipidemia treatment and 
risk of dementia or AD (Table S5). Among these, 25 studies reported results on statin therapy 
[46, 48-71], eight on nonstatin lipid-lowering agents [48, 50-52, 61, 62, 65, 66], and three on 
any lipid-lowering agent (statins or nonstatins) [58, 72, 73]. The combined RRs for statin use 
vs nonuse were 0.77 (95% CI, 0.63–0.95) for dementia, with notable heterogeneity among 
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studies, and 0.86 (95% CI, 0.80–0.92) for AD, with moderate heterogeneity (Figure 3). The 
associations of statin therapy with dementia and AD risk did not differ significantly by study 
quality, follow-up time, or number of cases (all p > 0.10; Table S6). High potency statins 
(i.e., atorvastatin, rosuvastatin, and simvastatin) appeared to be more strongly associated with 
reduced risk of dementia and AD than low potency statins (i.e., fluvastatin, lovastatin, and 
pravastatin) [55, 63, 68, 71] (Table S6). In seven studies that reported results on duration of 
statin use [49, 50, 66-69, 74], the combined RRs of dementia or AD were 0.83 (95% CI, 0.68–
1.01) for short-term use and 0.57 (95% CI, 0.40–0.82) for long-term use.  
Nonstatin lipid-lowering agents were not associated with dementia or AD risk in the 
overall analysis (Figure 4) or in stratified analysis by study quality, follow-up time, and 
number of cases (data not shown). Use of any lipid-lowering agent (statins or nonstatins) was 
associated with a lower risk of dementia/AD (RR, 0.47; 95% CI, 0.35–0.62; I2 = 48%). No 
evidence of publication bias was noted. 
 
Type 2 diabetes mellitus treatment 
Seven prospective studies of antidiabetic treatment in relation to risk of dementia or AD 
[56, 75-80] were identified (Table S7). In two cohorts of type 2 diabetes mellitus patients [77, 
79], the combined RRs of dementia or AD were 0.94 (95% CI, 0.91–0.97; I2 = 0%) for oral 
antidiabetic drug use and 1.17 (95% CI, 0.80–1.71; I2 = 68.2%) for insulin therapy. In four 
studies that included both diabetics and nondiabetics, the combined RRs of dementia or AD 
were 1.51 (95% CI, 0.83–2.77; I2 = 86.7%) for oral antidiabetic drug use [75-77] and 2.10 
(95% CI, 1.14–3.85; I2 = 55.0%) for insulin therapy [56, 75, 77], relative to nondiabetics.  
One study investigated whether metformin is associated with a lower incidence of 
dementia compared with sulfonylureas [80]. After accounting for confounding by indication, 
metformin vs sulfonylurea use was associated with a lower risk of dementia in those <75 
years of age but not in those ≥75 years of age [80] (Table S7). 
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DISCUSSION  
This systematic review found evidence that antihypertensive use may lower the incidence 
of dementia and AD. Statin use was related to a lower risk of dementia in prospective studies 
but not in the single RCT. There was no support for a beneficial effect of treatment with 
nonstatin lipid-lowering agents or antidiabetic drugs. Studies on smoking cessation, exercise, 
and weight loss interventions in relation to dementia or AD incidence were lacking, except for 
a small (<200 participants) multifactorial VRF intervention study showing no beneficial 
effect. This finding is consistent with a small lifestyle-based intervention showing no benefit 
of 24-month multidomain intervention with focus on improvement in lifestyle and vascular 
risk factors on the incidence of poststroke cognitive decline in comparison with standard 
stroke care [81].  
Four of the five RCTs of antihypertensive therapy observed a 12% to 55% reduction in 
dementia incidence in the active treatment group. However, the number of dementia cases in 
each RCT was limited and the results were statistically significant only in the Systolic 
Hypertension in Europe Study [21]. The inconsistent results may partly be related to different 
antihypertensive therapies, and to differences in the reduction in blood pressure in the active 
treatment and placebo groups. In the Study on Cognition and Prognosis in the Elderly trial, 
which did not show a lower dementia risk with treatment, patients were allocated to receive 
an angiotensin receptor blocker or placebo, with open-label active antihypertensive therapy 
added as needed [22]. This resulted in 84% of the placebo group taking additional 
antihypertensive medication. As a consequence, systolic and diastolic blood pressure at the 
end of follow-up was only marginally lower in the treatment group than in the placebo group. 
Other trials showed larger differences in the reduction in blood pressure between treatment 
arms. Different participant characteristics and diagnostic criteria for dementia may also have 
contributed to the inconsistent findings. The RCTs did not have dementia as the primary 
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endpoint [20-23] or the main trial was stopped early [24] and therefore was not powered to 
detect a statistically significant effect of blood pressure-lowering on dementia incidence. The 
prospective studies of any antihypertensive therapy and risk of dementia or AD were also 
generally based on a limited number of cases, ranging from 65 to 333 AD cases and 108 to 
440 dementia cases, but an overall statistically significant inverse association between any 
antihypertensive medication use and risk of AD was observed in the meta-analysis. 
AD begins many years before dementia symptoms emerge and VRF in midlife appear to 
be better related to dementia than VRF in old age [82]. The RCTs and most prospective 
studies of antihypertensive treatment and dementia risk were short term (2.2-5 years in the 
RCTs), or had short follow-up, and generally included older participants (≥60 years of age). 
The short-term antihypertensive treatment in old age may explain negative findings in RCTs 
and some of the prospective studies.  
Antihypertensive treatment might reduce the risk of dementia and AD by decreasing 
blood pressure or by specific neuroprotective effects. Hypertension is the major risk factor for 
cerebral white matter hyperintensities visible on T2-weighted MRI, which are associated with 
an increased risk of dementia [83]. In the Perindopril Protection Against Recurrent Stroke 
Study trial, antihypertensive therapy delayed the progression of white matter hyperintensities 
[84] and reduced the incidence of dementia by 34% in patients with recurrent stroke but had 
no effect on dementia incidence in the absence of recurrent stroke [23]. Antihypertensive 
drugs that cross the blood-brain barrier may have specific neuroprotective actions. For 
example, an experimental study in mice showed that the calcium channel blocker nifedipine, 
which can cross the blood-brain barrier, attenuated peroxide anion production in the brain and 
this reduction in oxidative stress was related to better cognitive performance [85]. Two other 
experimental studies showed that certain calcium channel blockers, including nifedipine and 
nitrendipine (the antihypertensive drug used in the Systolic Hypertension in Europe Study 
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[21]), decreased brain Aβ peptide concentrations [86, 87] and improved Aβ clearance across 
the blood-brain barrier [86]. A prospective study found that angiotensin-converting	enzyme 
inhibitors that cross the blood-brain barrier were more strongly inversely associated with AD 
risk than angiotensin converting	enzyme-inhibitors that cannot cross the blood-brain barrier 
[41].  
Results from the present meta-analysis of prospective studies showed that statin therapy 
was associated with a reduced risk of dementia and AD. However, a large RCT did not 
support a reduction in dementia incidence with simvastatin therapy [25]. Whether 
hypercholesterolemia is a risk factor for dementia and AD remains elusive. Observational 
studies have found that hypercholesterolemia in midlife is associated with AD risk [7], but 
Mendelian randomization studies, which are less prone to bias, do not support a causal 
association between cholesterol levels and AD [88, 89]. Statins may have neuroprotective 
actions through their ability to improve blood-flow, modulate the immune system and lower 
oxidative damage [90].  
A meta-analysis of published studies inherits the limitations of the original studies. 
Observational studies are susceptible to confounding and reverse causality and we cannot rule 
out the possibility that these biases may have affected the results. Another potential limitation 
is the accuracy of dementia diagnosis and differentiation of AD from other causes of 
dementia. An AD diagnosis based on standard criteria has good sensitivity and specificity for 
differentiating between AD patients and individuals without dementia but the ability to 
discern between AD and other causes of dementia is less accurate [3]. Another shortcoming is 
that the literature search and data extraction were performed by a single investigator, and that 
only one database was searched. We therefore cannot preclude the possibility that we may 
have missed relevant studies for inclusion. Finally, as a meta-analysis of published studies, 
the possibility that publication bias may have affected the results cannot be excluded. We 
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found no evidence of such bias but tests for publication bias have low power, in particular 
when the number of studies is limited. 
In conclusion, available evidence from RCTs and prospective studies indicates that 
antihypertensive therapy might have a role in preventing dementia and AD. Further studies 
are required, particularly on whether more intensive lowering of blood pressure to 120 mm 
Hg systolic or below, which has been shown to reduce cardiovascular outcomes [91], is also 
associated with a lowering of the incidence of dementia and AD. Prospective studies have 
indicated an inverse association between statin use and risk of dementia and AD, but there is 
yet no support from RCTs that statins are beneficial.  
A striking feature was the paucity of RCTs investigating the effect of treatment of 
vascular risks factors on AD. A cost-efficient method of obtaining such data would be to 
include long-term follow-up for cognitive endpoints in trials of cardiovascular prevention. 
This is important considering both the huge population burden of dementia, and the lack of 
other effective treatment approaches.  
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Table 1 
Number of randomized controlled trials and prospective studies included in the review 
Vascular risk factor and drug treatment or 
intervention 
No. of randomized 
controlled trials 
No. of prospective 
studies 
Hypertension    
    Antihypertensive drug use vs. nonuse/placebo 5 13 
    Comparison of antihypertensive drug classes 0 7 
Hyperlipidemia    
    Statin 1 25* 
    Nonstatin lipid-lowering drug 0 8* 
    Any lipid-lowering drug (statin or nonstatin) 0 3* 
Type 2 diabetes mellitus   
    Oral antidiabetic drug 1 6† 
    Insulin therapy  0 5† 
Vascular risk factor intervention   
    Smoking cessation  0 0 
    Exercise  0 0 
    Weight loss  0 0 
    Multifactorial intervention 1 0 
*Some studies provided results on both statins and nonstatins or a combination of these. 
†Most studies provided results on both oral antidiabetic drugs and insulin therapy.
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Fig. 1. Relative risks of dementia for antihypertensive treatment vs placebo in individual 
randomized controlled trials and all trials combined. Trials are ordered by year of publication. 
Squares represent trial-specific relative risk (RR) (size of the square reflects the trial-specific 
statistical weight); the horizontal lines represent 95% confidence intervals (CIs); diamond 
represents combined RR with its 95% CI. HYVET-COG, Hypertension in the Very Elderly 
Trial-Cognition; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; 
SCOPE, Study on Cognition and Prognosis in the Elderly; SHEP, Systolic Hypertension in 
the Elderly Program; SYST-EUR, Systolic Hypertension in Europe Study.  
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Fig. 2. Combined relative risks of dementia and Alzheimer’s disease for use of any 
antihypertensive drug and classes of antihypertensive drugs vs nonuse in prospective studies. 
Results for antihypertensive drug classes are for dementia or Alzheimer’s disease. *Number 
of studies in each subgroup. ACE-I, angiotensin-converter enzyme inhibitor; AH, anti-
hypertensive; CI, confidence interval; RR, relative risk.  
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Fig. 3. Relative risks of dementia and Alzheimer’s disease for statin use vs nonuse in 
individual prospective studies and all studies combined. *First author’s last name and year of 
publication. Studies are ordered by year of publication. NS, not specified; M, men; W, 
women. Squares represent study-specific relative risks (RR) (size of the square reflects the 
study-specific statistical weight); the horizontal lines represent 95% confidence intervals 
(CIs); diamonds represent the combined RR with its 95% CI. 
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Fig. 4. Forest plot of prospective studies of nonstatin lipid-lowering agent use vs nonuse in 
relation to incidence of dementia and Alzheimer’s disease.  *First author’s last name and year 
of publication. LLA, lipid-lowering agent; M, men; W, women. Squares represent study-
specific relative risks (RR) (size of the square reflects the study-specific statistical weight); 
the horizontal lines represent 95% confidence intervals (CIs); diamonds represent the 
combined RR with its 95% CI. 
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Table S1: Search terms used for the electronic database search 
(Alzheimer's Disease OR Alzheimer OR dementia) AND (vascular risk factor OR 
hypertension OR blood pressure OR antihypertensive agents OR angiotensin 
converting enzyme inhibitors OR angiotensin receptor blockers OR beta blockers 
OR calcium channel blockers OR diuretics OR hyperlipidemia OR 
hypercholesterolemia OR cholesterol OR lipid lowering agents OR statins OR 
diabetes OR antidiabetic agents OR hypoglycemic agents OR glucose control OR 
insulin therapy OR overweight OR obesity OR weight loss OR exercise OR 
physical activity OR smoking) AND (randomized controlled trial OR clinical trial 
OR intervention study OR prospective study OR cohort study OR follow-up study 
OR longitudinal study OR nested case-control study) 
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Table S2: Randomized controlled trials of hypertension treatment and incidence of dementia  
Reference Trial name, 
country 
Participant characteristics Mean 
Follow-
up, years 
No. of dementia 
cases; diagnostic 
criteria  
Antihypertensive 
medication  
∆SBP/DBP 
(active–placebo) 
RR (95% CI)  
of dementia 
 
SHEP 
Research 
Group, 
1991 [1] 
SHEP, United 
States 
4736 adults (43% men) ≥60 
years of age; SBP 160–219 
mmHg, DBP <90 mmHg; 
no history of major CVDs 
5 81; expert diagnosis 
evaluation (Short-
Care Test) 
Diuretic (chlorthalidone) ± β-
blocker (atenolol) vs placebo 
 
–11.1/3.4 mmHg 0.84 (0.55–1.30)* 
 
Forette et al, 
2002 [2] 
SYST-EUR, 
19 countries 
2902 adults (34% men) ≥60 
years of age; SBP 160–219 
mmHg, DBP <95 mmHg 
3.9 64; DSM-III-R and 
results of CT scan 
CCB (nitrendipine) ± diuretic 
(hydrochlorothiazide), ACE-I 
(enalapril) or both drugs vs 
placebo 
–7.0/3.2 mmHg 0.45 (0.27–0.76) 
 
Lithell et al, 
2003 [3] 
SCOPE, 15 
countries 
4937 adults (36% men) 70–89 
years of age; SBP 160–179 
mmHg, DBP 90–99 mmHg; 
MMSE score ≥24 
3.7 119; modified ICD-
10 research criteria 
ARB (candecertan) ± diuretic 
(hydrochlorothiazide) vs placebo 
 
–3.2/1.6 mmHg 1.08 (0.76–1.54)* 
 
Tzourio et al, 
2003 [4] 
PROGRESS, 
10 countries 
6105 adults (70% men), mean 
age 64 years; prior stroke or 
transient ischemic attack 
3.9 410; DSM-IV  ACE-I (perindopril) ± diuretic 
(indapamide) vs placebo 
 
–9/4 mmHg 0.88 (0.72–1.08) 
Peters et al, 
2008 [5] 
HYVET-COG, 
13 countries 
3336 adults (40% men) ≥80 
years of age; SBP 160–200 
mmHg, DBP <110 mmHg 
2.2 263; DSM-IV and 
results of CT scan 
Diuretic (indapamide) ± ACE-I 
(perindopril) vs placebo 
–15/5.9 mmHg 0.86 (0.67–1.09) 
[0.85 (0.63–1.15) for 
Alzheimer’s disease 
and 0.87 (0.57–1.34) 
for vascular dementia] 
Abbreviations: ACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CT, 
computerized tomography; CVD, cardiovascular disease; CI, confidence interval; CT, computed tomography; DBP, diastolic blood pressure; DSM, 
Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; HYVET-COG, Hypertension in the Very Elderly Trial-
Cognition; MMSE, Mini-Mental State Examination; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; RR, relative risk; SBP, systolic 
blood pressure; SCOPE, Study on Cognition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; SYST-EUR, Systolic 
Hypertension in Europe Study. 
*The risk estimate was not reported in the article but was estimated based on the number of cases and non-cases in the two treatment arms. 
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Table S3: Prospective studies of antihypertensive medication use vs nonuse and incidence of dementia and Alzheimer’s disease 
Reference Study name, country Participants; 
baseline age  
Mean 
follow-up, 
years 
Outcome (No. of cases); 
diagnostic criteria 
NOS 
score 
Adjustments Adjusted RR (95% CI) of dementia or 
AD for AH drug use vs nonuse 
Morris et al, 
2001 [6] 
East Boston Study, 
United States 
634 adults; 
≥65 years 
4 AD (n=99); NINCDS-
ADRDA 
7 Age, sex, education BB, 0.91 (0.26–3.17) 
Diuretics, 1.03 (0.63–1.65) for any, 1.06 
(0.37–3.06) for loop, 1.33 (0.68–2.61) 
for thiazide, and 0.63 (0.26–1.54) for 
potassium-sparing 
in’t Veld, et 
al, 2001 [7] 
Rotterdam Study, The 
Netherlands 
7046 adults; 
≥55 years 
2.2 Dementia (n=118), 
AD (n=82); DSM-III-R, 
NINCDS-ADRDA 
8 Age, sex, education, living situation, BMI, 
smoking, diabetes, stroke, PAD, DBP, SBP, 
baseline MMSE 
Any AH, dementia: 0.67 (0.45–1.00); 
AD: 0.77 (0.49–1.24) 
Lindsay et al, 
2002 [8] 
Canadian Study of 
Health and Aging, 
Canada 
4088 adults; 
≥65 years 
5 AD (n=194); NINCDS-
ADRDA 
7 Age, sex, education Any AH, 0.91 (0.64–1.30) 
Yasar et al, 
2005 [9] 
Baltimore Longitudinal 
Study of Aging, 
United States 
1092 adults; 
≥60 years 
11 AD (n=115); DSM-III-R, 
NINCDS-ADRDA 
7 Age, sex, education, smoking, blood pressure, 
heart disease 
CCB, 0.63 (0.31–1.28) [0.30 (0.07–
1.25) for dihydropyridine and 0.82 
(0.37–1.83) for nondihydro-pyridine] 
Peila et al, 
2006 [10] 
Honolulu Asia Aging 
Study, United States 
1294 men; 
≥72 years 
5 
 
Dementia (n=108), 
AD (n=65); DSM-III-R, 
DSM-IV, NINCDS-
ADRDA 
8 Age, sex (all men), education, APOE-ε4 
status, blood pressure, BMI, smoking status, 
coronary heart disease 
Any AH, dementia: 0.59 (0.35–1.00)*; 
AD: 0.48 (0.29–0.78)*  
Qiu et al, 2006 
[11] 
Kungsholmen Project, 
Sweden 
1301 adults; 
75–101 
years 
5 
 
Dementia (n=440), 
AD (n=333); DSM-III-
R, NINCDS-ADRDA 
9 Age, sex, education, follow-up survival status, 
BMI, diabetes, heart failure, stroke, pulse 
rate, SBP, DBP, baseline MMSE 
Any AH, dementia: 0.92 (0.75–1.13); 
AD: 0.84 (0.67–1.07)  
Johnson et al, 
2012 [12] 
Cohort from Veterans 
Administration, 
United States 
377 838 
adults; ≥65 
years 
2 Dementia (n=14 580); 
ICD-9-CM codes  
6 Age, sex, ethnicity, comorbidities, co-
medications 
ACE-I, 0.89 (0.85–0.93) 
ARB, 0.76 (0.70–0.83) 
BB, 0.96 (0.92–0.995) 
CCB, 0.93 (0.89–0.97) 
Diuretic, 0.86 (0.83–0.90) 
Qui et al, 2013 
[13] 
National Alzheimer’s 
Disease Coordinating 
Center, United States 
4830 adults; 
mean age 
76 years 
3.4 AD (n=1331); DSM-IV, 
NINCDS-ADRDA 
6 Age, sex, ethnicity, education, smoking, 
drinking, follow-up time, diabetes, 
hypertension, stroke, heart failure, mild 
cognitive impairment 
ACE-I, 0.77 (0.67–0.89)† [0.79 (0.67–
0.93) for central ACE-I and 0.73 
(0.57–0.94) for peripheral ACE-I] 
Yasar et al, 
2013 [14] 
Ginkgo Evaluation of 
Memory Study, 
United States  
1928 adults; 
≥75 years 
5.6 AD (n=290); DSM-IV, 
NINCDS-ADRDA 
9 Age, sex, education, income, BMI, SBP, DBP, 
vascular diseases, mild cognitive 
impairment 
ACE-I, 0.56 (0.37–0.85) 
ARB, 0.35 (0.19–0.65) 
BB, 0.64 (0.44–0.72)  
Diuretic, 0.46 (0.32–0.68) 
Chiu et al, 
2014 [15] 
National Health 
Insurance Research 
140 140 
adults; >50 
10.3 Dementia (n=11 075); 
ICD-9 codes 290.0–
8 Age, sex, income, urbanization, hypertension, 
coronary heart disease, diabetes, 
ACE-I, dementia: 1.14 (1.08–1.19); AD: 
1.11 (0.98–1.26) 
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Database, Taiwan years 290.4, 294.1, 331.0 hypercholesterolemia, depressive disorder, 
heart failure, chronic kidney disease, stroke 
ARB, dementia: 0.59 (0.56–0.62); AD: 
0.61 (0.54–0.68)‡  
BB, dementia: 1.00 (0.95–1.04); AD: 
1.18 (1.05–1.33) 
CCB, dementia: 0.81 (0.77–0.84); AD: 
0.76 (0.68–0.86) 
Diuretic, dementia: 0.87 (0.83–0.91); 
AD: 0.78 (0.68–0.90) 
Chuang et al, 
2014 [16] 
Cache County Study, 
United States 
3227 adults; 
≥65 years 
7.1 AD (n=325); DSM-III-R, 
NINCDS-ADRDA 
8 Age, sex, education, APOE-ε4 status, smoking 
and drinking habits, history of high 
cholesterol, diabetes, stroke, coronary artery 
bypass graft, and myocardial infarction 
Any AH, 0.76 (0.60–0.96) 
ACE-I, 0.95 (0.71–1.29) 
BB, 0.90 (0.67–1.21) 
CCB, 0.75 (0.55–1.04) [0.75 0.48–1.17) 
for dihydropyridine and 0.88 (0.60–
1.30) for non-dihydropyridine] 
Diuretic (any), 0.72 (0.56–0.93) [0.98 
(0.67–1.43) for loop, 0.70 (0.53–0.93) 
for thiazide, and 0.69 (0.48–0.99) for 
potassium-sparing] 
Chitnis et al, 
2015 [17] 
Medicare Advantage 
Prescription Drug, 
United States 
8062 adults; 
mean age 
75 years 
3 Dementia (n=1135); ICD-
9-CM codes 046.1, 
046.0, 290.0–290.4, 
291.2, 292.82, 294.10, 
294.11, 294.8, 294.9, 
331.0, 331.11, 331.19, 
331.2, 331.7, 331.82, 
331.89, 331.9 
7 43 time-independent factors (e.g., 
sociodemographic, treatment, and clinical 
factors) and time-dependent factors updated 
monthly (e.g., exposure groups, duration of 
use, medication possession ratio, and 
hospitalization) 
ACE-I/ARB, 0.90 (0.70–1.16) for 
current use and 0.89 (0.71–1.10) for 
former use  
Tully et al., 
2016 [18] 
3C Study, France 6537 adults; 
≥65 years 
8.4 Dementia (n=446); 
NINCDS-ADRDA 
9 Age, sex, center, education, BMI, CVD, 
diabetes, hypercholesterolemia, Center for 
Epidemiologic Studies Depression Scale, 
chronic kidney disease, APOE4, SBP, DBP 
ACE-I, 0.87 (0.64–1.18); ARB, 0.87 
(0.58–1.31); BB, 1.13 (0.85–1.51); 
CCB, 0.56 (0.31–1.00); Diuretics, 
0.45 (0.22–0.93) for loop, 0.91 (0.40–
2.05) for thiazide, and 0.83 (0.55–
1.25) for potassium-sparing 
Abbreviations: AD, Alzheimer’s disease; ACE-I, angiotensin converting enzyme-inhibitor; AH, antihypertensive; ARB, angiotensin receptor blocker; APOE, 
apolipoprotein E; BB, β-blockers; BMI, body mass index; CCB, calcium channel blockers; CI, confidence interval; DBP, diastolic blood pressure; DSM, 
Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; NINCDS-ADRDA, National Institute of Neurological 
and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association; NOS, New-Castle Ottawa Scale (quality assessment of 
prospective studies); MMSE, Mini-Mental State Examination; PAD peripheral atherosclerotic disease; RR, relative risk; SBP, systolic blood pressure. 
*The risk estimate was obtained by combining the reported risk estimates for 0–5, 5–12, and >12 years of use. 
†The risk estimate was obtained by combining the reported risk estimates for central and peripheral ACE-I. 
‡For both dementia and AD, the inverse association was stronger with higher cumulative dose and longer duration of ARB use. 
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Table S4: Prospective studies comparing different classes of antihypertensive drugs and incidence of dementia and Alzheimer’s disease 
Reference Study name, country 
 
Participants; 
baseline age 
Mean 
follow-up, 
years 
Outcome (No. of cases); 
diagnostic criteria 
NOS 
score 
Adjustments Adjusted RR (95% CI) of dementia or 
AD comparing different AH drug 
classes  
Ohrui et al, 
2004 [19] 
No name, Japan 4124 adults; 
≥65 years 
8 AD (n=90); NS 1 NS No difference in AD risk for ACE-I, BB, 
CCB, or diuretics; however, among 
ACE-I users, the use of ACE-Is that 
inhibit brain ACE, compared with other 
ACE-Is, was associated with a lower risk 
of AD (0.25; 0.08–0.75) 
Sink et al, 2009 
[20] 
Cardiovascular Health 
Study, United States 
1054 adults; 
≥65 years 
6 Dementia (n=158); DSM-
IV, NINCDS-ADRDA 
8 Age, sex, race, education, income, 
smoking, alcohol, diabetes, 
coronary artery disease, serum 
creatinine, serum low-density 
lipoprotein, MMSE, depression  
ACE-I vs other AH medications, 1.05 
(0.91–1.21) 
Li et al, 2010 
[21] 
 
US Veterans Affairs 
Health System, United 
States 
799 069 
(dementia); 
819 491 
(AD); ≥65 
years 
4 Dementia (NS), AD (NS); 
ICD-9 codes (NS) 
6 Age, sex (98% men), diabetes, stroke, 
cardiovascular disease 
ARB vs ACE-I, dementia: 0.81 (0.73–
0.90); AD: 0.81 (0.68–0.96) 
ARB vs cardiovascular comparator (BB or 
CCB): dementia: 0.76 (0.69–0.84); AD: 
0.84 (0.71–1.00) 
Davies et al, 
2011 [22] 
 
General Practice 
Research Database, 
United Kingdom 
9197 cases 
and 39 166 
controls; 
≥60 years  
NS Dementia (n=9197), 
AD (n=5797); NS 
6 Age, sex, region, diabetes, stroke, 
coronary artery disease, blood 
pressure, number of consultations 
ARB vs other AH medications, dementia: 
0.55 (0.49–0.62); AD: 0.47 (0.37–0.58) 
ACE-I vs other AH medications, dementia: 
0.80 (0.76–0.84); AD: 0.76 (0.69–0.84)  
Hsu et al, 2013 
[23] 
National Health 
Insurance Research 
Database, Taiwan 
32 911 adults; 
mean age 58 
years 
5.2 Dementia (n=1031); ICD-9 
codes 290.0, 290.20, 
290.21, 290.3, 331.0 
9 Age, sex, diabetes, coronary artery 
disease, arrhythmia, hypertension, 
hyperlipidemia 
ARB vs other AH medications, 1.00 (0.88–
1.13) 
Goh et al., 
2015 [24] 
Clinical Practice 
Research Datalink, 
United Kingdom 
426 089 
adults; ≥18 
years 
4.3 Dementia (n=6517); Read 
codes 
6 Age, sex, calendar year, SES, number 
of consultations, BMI, smoking, 
diabetes, hypertension, heart failure, 
statin use, alcohol use 
ARB vs ACE-I, 0.92 (0.85–1.00)  
Hwang et al, 
2017 [25] 
National Health 
Insurance Service 
Senior Cohort, Korea 
18 423 adults; 
≥60 years 
9.6 Dementia (4005); AD 
(1987); ICD-10 codes 
F00-F07, G20-G26, G30-
G32 
9 Age, sex, BMI, income, urbanization, 
smoking, alcohol, blood pressure, 
hypertensive drugs, CAD, diabetes, 
hypercholesterolemia,  
CCB vs non-CCB, dementia: 0.81 (0.75-
0.87); AD: 0.80 (0.72-0.88) 
Abbreviations: AD, Alzheimer’s disease; ACE-I, angiotensin converting enzyme-inhibitor; AH, antihypertensive; ARB, angiotensin receptor blocker; BB, β-blockers; BMI, 
body mass index; CCB, calcium channel blockers; CI, confidence interval; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of 
Diseases; MMSE, Mini-Mental State Examination; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease 
Related Disorders Association; NOS, Newcastle Ottawa Scale (quality assessment of prospective studies); NS, not specified; SES, socioeconomic status; RR, relative risk. 
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Table S5: Prospective studies of hyperlipidemia medication use vs nonuse and incidence of dementia and Alzheimer’s disease  
       Adjusted RR (95% CI)  
Reference Study name, country Participants; 
baseline age 
Mean 
Follow-
up, years 
Outcome (No. of cases); 
diagnostic criteria 
NOS 
score 
Adjustments Statins Non-statin LLAs 
 
Jick et al, 
2000 [26] 
 
General Practice 
Research Database, 
United Kingdom  
284 cases and 
1080 controls; 
≥50 years 
NS Dementia (n=284); NS  
 
5 Age, sex, calendar time, practice, BMI, 
smoking, diabetes, years of recorded 
history in database, hypertension, CAD, 
coronary artery bypass surgery, TIA 
0.29 (0.13–0.63) 
 
0.96 (0.47–1.97) 
Reitz et al, 
2004 [27] 
Washington Heights, 
United States 
1168 adults; 
≥65 years 
4.4 AD (n=119); DSM-III-R, 
NINCDS-ADRDA 
8 Age, sex, education, race, BMI, diabetes, 
hypertension, heart disease, APOE-ε4 
NA 0.61 (0.42–0.87) 
for any LLAs  
Zamrini et al, 
2004 [28] 
 
US Veterans Affairs 
Medical Center, 
United States 
309 male cases, 
3088 male 
controls; ≥50 
years 
NS AD (n=309); ICD-9-CM 
codes 290.0, 290.10, 
290.13, 290.20, 
290.21, 290.3, 331.0 
6 Age, sex (all men), diabetes, lipid 
metabolism disorders, hypertension, 
CAD, cerebrovascular disease, arterial 
disease 
0.61 (0.42–0.87) NA 
Li et al, 2004 
[29] 
Adult Changes in 
Thought Study, 
United States 
2356 adults; 
≥65 years 
5.6 Dementia (n=312); 
DSM-IV, NINCDS-
ADRDA 
9 Age, education, APOE-ε4, use of other 
LLAs or statins; no adjustments for sex, 
BMI, and comorbidities because of lack 
of association with dementia/AD  
1.19 (0.82–1.75) 1.01 (0.67–1.52) 
Zandi et al, 
2005 [30] 
Cache County Study, 
United States 
3308 adults; 
≥65 years 
3 Dementia (n=182), 
AD (n=102); DSM-III-
R, NINCDS-ADRDA 
8 Age, sex, education, diabetes, 
hypertension, APOE-ε4, age*ε4 
interaction 
Dementia: 1.19 
(0.53–2.34); AD: 
1.19 (0.35–2.96) 
Dementia: 1.71 
(0.51–4.20)  
Rea et al, 
2005 [31] 
Cardiovascular Health 
Study, United States 
2798 adults; 
≥65 years 
5.4 Dementia (n=466), 
AD (n=237); DSM-IV, 
NINCDS-ADRDA 
8 Age, sex, education, baseline MMSE, 
CAD, stroke, alcohol use 
Dementia: 1.08 
(0.77–1.52); AD: 
1.21 (0.76–1.91) 
Dementia: 0.86 
(0.50–1.46); AD: 
1.05 (0.51–2.13) 
Szwast, et al, 
2007 [32] 
Indianapolis Ibadan 
Dementia Project, 
United States 
1141 adults; 
≥65 years 
3  Dementia (n=32); DSM-
III-R and ICD-10 
codes (NS) 
6 Age, sex, education, APOE-ε4  0.32 (0.07–1.42) NA 
Zigman et al, 
2007 [33] 
No name, United States 123 adults; 41–
78 years 
5.5 AD (n=38); NS 3 NS 0.40 (0.14–1.17) NA 
Wolozin et al, 
2007 [34] 
US Veteran Affairs 
Medical Center, 
United States 
727 128 adults 
(94.4% men); 
≥65 years 
2.4 Dementia/AD (n=2647); 
ICD-9 code 331.0 (may 
not fulfill all NINCDS-
ADRDA criteria) 
8 Age, diabetes, obesity, hypertension, 
cardiovascular diseases, Charlson 
Comorbidity Index; no adjustment for 
sex but 94.4% were men 
0.46 (0.44–0.48)* NA 
Fischer et al, 
2008 [35] 
Vienna Transdanube 
Aging Study, Austria 
479 adults; age 
75 years 
2.5 AD (n=90); DSM-IV, 
NINCDS-ADRDA 
6 None 0.98 (0.87–1.10) NA 
Cramer et al, 
2008 [36] 
Sacramento Area Latino 
Study on Aging, 
United States 
1674 adults; 
≥60 years 
4.5 Dementia (n=130); 
DSM-IV, NINCDS-
ADRDA 
9 Age, sex (no confounding and therefore 
no adjustment), education, smoking, 
diabetes, stroke, APOE-ε4, MMSE  
0.56 (0.37–0.87) NA 
Sparks et al, Alzheimer’s Disease 2233 adults; 4 AD (n=25); DSM-IV, 7 Age, sex, education, APOE-ε4  0.33 (0.11–0.98) 0.33 (0.12–0.89) 
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2008 [37] Anti-inflammatory 
Prevention Trial, 
United States 
≥70 years NINCDS-ADRDA NA for any LLAs 
Arvanitakis et 
al, 2008 
[38] 
Religious Orders Study, 
United States  
929 adults; 
mean age 75 
years 
12 AD (n=191); NINCDS-
ADRDA 
8 Age, sex, education 0.91 (0.54–1.52) NA 
Smeeth et al, 
2009 [39] 
Health Improvement 
Network database, 
United Kingdom 
729 529 adults; 
40–80 years 
4.4 Dementia (n=5172), AD 
(n=725); NS 
6 Age, sex, propensity score, year of index 
date, first diagnosis of any disease, first 
use of any medication 
Dementia: 0.81 
(0.69–0.96); AD: 
0.81 (0.49–1.35) 
NA 
Haag et al, 
2009 [40] 
Rotterdam Study, The 
Netherlands 
6992 adults; 
≥55 years 
9 AD (n=582); DSM-III-R, 
NINCDS-ADRDA 
9 Age, sex, education, BMI, smoking, 
diabetes, SBP, cholesterol, 
cardiovascular and cerebrovascular 
disease, non-statin LLAs or statins 
0.57 (0.37–0.90)  1.05 (0.45–2.44) 
Solomon et al, 
2010 [41] 
FINRISK, Finland 17 597 adults; 
mean age 67–
72 years 
NS Dementia (n=1561); NS 8 Age, sex, education, survey region and 
year, BMI, total cholesterol, systolic 
blood pressure 
NA 0.42 (0.37–0.49) 
for any LLAs 
Li et al, 2010 
[42] 
Adult Changes in 
Thought Study, 
United States 
3099 adults; 
≥65 years 
 
6.1 AD (n=263); DSM-IV, 
NINCDS-ADRDA 
9 Age, sex, cohort, race, education, BMI, 
smoking, CASI score, comorbid 
vascular diseases, use of other LLAs, 
APOE-ε4  
0.62 (0.40–0.97) 1.28 (0.82–1.99)† 
Hippisley-Cox 
et al, 2010 
[43] 
Egton Medical 
Information System, 
United Kingdom 
2 004 692 
adults; 30–84 
years 
7 Dementia (n=8784); NS 5 Age, sex 0.92 (0.83–1.02) in 
men and 0.88 
(0.81–0.96) in 
women*  
NA 
Beydoun et al, 
2011 [44] 
Baltimore Longitudinal 
Study of Aging, 
United States 
1604 adults; 
≥50 years 
24.9 Dementia (n=259); 
DSM-IIII-R, NINCDS-
ADRDA 
9 Age, sex, race/ethnicity, education, BMI, 
smoking, diabetes, hypertension, SBP, 
CAD, dyslipidemia 
0.41 (0.18–0.92) NA 
Ancelin et al, 
2012 [45] 
No name, France 7056 adults; 
≥65 years 
6.7 Dementia (n=483), 
AD (n=332); DSM-IV, 
NINCDS-ADRDA 
 
7 Age, sex, center, education Dementia: 0.81 
(0.53–1.23) in 
men; 1.20 (0.88–
1.64) in women; 
AD: 1.09 (0.67–
1.76) in men, 1.17 
(0.80–1.70) in 
women 
Dementia: 0.85 
(0.53–1.36) in men, 
1.08 (0.77–1.52) in 
women; AD: 1.04 
(0.60–1.80) in men, 
1.12 (0.75–1.66) in 
women 
Bettermann et 
al, 2012 
[46] 
Ginkgo Evaluation of 
Memory Study, 
United States 
2587 adults; 
≥65 years 
 
5.6 Dementia (n=324), 
AD (n=212); DSM-IV, 
NINCDS-ADRDA 
9 Age, sex, race, field center, education, 
Ginkgo biloba randomization group, 
APOE-ε4, stroke, CAD 
Dementia: 0.77 
(0.60–0.98); AD: 
0.83 (0.61–1.12) 
 
Dementia: 0.65 
(0.37–1.14); AD: 
0.48 (0.21–1.08) 
Corrao et al, 
2013 [47] 
National Health Service, 
Italy 
152 729 adults; 
≥40 years 
NS Dementia (n=1380); 
ICD-9-CM codes (>10 
7 Age, sex, date of index prescription, 
concomitant users of other drugs, 
0.78 (0.70–0.87)‡ NA 
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codes) Charlson Comorbidity Index 
Chou et al, 
2014 [48] 
National Health 
Insurance Research 
Database, Taiwan 
33 398 adults; 
≥60 years 
5 AD (NS); ICD-9-CM 
codes 290.x, 294.1, 
331.0, A210 
9 Age, sex, SES, comorbidities, propensity 
scores 
0.78 (0.72–0.85)  NA 
Wu et al, 2015 
[49] 
National Health 
Insurance Research 
Database, Taiwan 
57 669 adults; 
≥65 years 
11.8 Dementia (5516); ICD-9-
CM codes 290.0, 
290.10–290.13 
9 Age, sex, hypertension, diabetes, chronic 
kidney disease, stroke, TIA, 
cardiovascular disease, heart failure, 
atrial fibrillation, medication use 
0.62 (0.41–0.92)§ 
 
NA 
Goh et al, 
2015 [24] 
Clinical Practice 
Research Datalink, 
United Kingdom 
426 089 adults; 
≥18 years 
4.3 Dementia (n=6517); 
Read codes 
6 Age, sex, calendar year, number of 
consultations, SES, BMI, smoking, 
diabetes, hypertension, heart failure, 
statin use, alcohol use 
1.03 (0.98–1.09) 
 
NA 
Chitnis et al, 
2015 [50] 
Medicare Advantage 
Prescription Drug, 
United States 
8062 adults; 
mean age 75 
years 
1.8 Dementia (n=1135); 
ICD-9-CM codes (>10 
codes) 
6 Age, sex, 44 time-independent factors 
such as socio-demographic and 
treatment factors, and comorbidities 
0.96 (0.81–1.15)ǁ 
 
 
NA 
Zissimopoulos 
et al, 2016 
[51] 
Medicare fee for 
service, United States 
399 979 adults; 
≥65 years 
7.2 AD (NS); CD-9-CM 
code 331.0 
9 Matched by age, sex, race/ethnicity, 
region, years since hyperlipidemia 
diagnosis, education, and health status 
0.88 (0.83-0.93) 
men; 0.85 (0.82-
0.89) women 
NA 
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; BMI, body mass index; CAD, coronary artery disease; CASI, Cognitive Abilities 
Screening Instrument; CI, confidence interval; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; 
LLA, lipid-lowering agents; MMSE, Mini-Mental State Examination; NA, not available; NINCDS-ADRDA, National Institute of Neurological and 
Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association; NOS, New-Castle Ottawa Scale (quality assessment of 
prospective studies); NS, not stated; RR, relative risk; SBP, systolic blood pressure; SES, socioeconomic status; TIA, transient ischemic attack. 
*Results for simvastatin were used in the main meta-analysis because simvastatin was the most frequently prescribed statin. Results for other statins were 
used in subgroup analyses by type of statins. 
†The risk estimate was obtained by combining the reported risk estimates for those <80 years and ≥80 years of age. 
‡The risk estimate was obtained by combining the reported risk estimates for prescriptions of 7–24 months, 25–48 months, and >48 months. 
§The risk estimate was obtained by combining the reported risk estimates for the three groups of accumulated dose. 
ǁThe risk estimate was obtained by combining the reported risk estimates for current and former users. 
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Table S6: Combined relative risks of dementia and Alzheimer’s disease for statin use vs nonuse in 
prospective studies, stratified by duration of follow-up, number of cases, degree of adjustment for 
potential confounders, and statin type 
 Dementia  Alzheimer’s disease 
 No. of  
studies* 
Combined  
RR (95% CI) 
I2†  No. of 
 studies* 
Combined  
RR (95% CI) 
I2† 
Study quality (NOS)        
    0–7 11 0.87 (0.78–0.97) 79%  6 0.93 (0.74–1.16) 38% 
    8–9  8 0.73 (0.52–1.01) 90%  7 0.79 (0.69–0.91) 20% 
Duration of follow-up        
    <5 years 7 0.74 (0.49–1.13) 99%  4 0.88 (0.65–1.19) 31% 
    ≥5 years 9 0.90 (0.80–1.00) 48%  9 0.84 (0.71–0.98) 44% 
No. of cases        
    <200  4 0.72 (0.50–1.04) 33%  6 0.91 (0.72–1.16) 27% 
    ≥200 15 0.78 (0.63–0.98) 98%  6 0.84 (0.66–1.07) 51% 
Statin type§        
    Atorvastatin 5 0.84 (0.80–0.89) 39%  --- --- --- 
    Fluvastatin 3 0.90 (0.76–1.06) 0%  --- --- --- 
    Lovastatin 2 0.95 (0.88–1.03) 0%  --- --- --- 
    Pravastatin 4 0.90 (0.78–1.04) 52%  --- --- --- 
    Rosuvastatin 5 0.72 (0.57–0.91) 68%  --- --- --- 
    Simvastatin 5 0.78 (0.58–1.04) 99%  --- --- --- 
Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; NOS, Newcastle Ottawa Scale; RR, 
relative risk. 
*The number of studies may not sum up to the total number of studies because of lack of information on 
duration of follow-up or number of cases. Hippisley-Cox et al 2010 [43], Ancelin et al [45], and 
Zissimopoulos [51] reported results stratified by sex; for these two studies, results for men and women were 
counted as two separate studies. 
†Describes the proportion of total variation in study estimates that is due to heterogeneity. I2 values of <30%, 
30%–75%, and >75% were considered no or marginal, moderate, and notable heterogeneity, respectively. 
‡Defined as adjustment for age, sex (if applicable), and at last five additional major risk factors (e.g., 
education, smoking, physical inactivity, obesity, diabetes, blood pressure or hypertension, cholesterol 
concentration or hyperlipidemia, cardiovascular diseases, depression, APOE-ε4) or Charlson Comorbidity 
Index. 
§The outcome for these analyses was either all-cause dementia or Alzheimer’s disease.   
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Table S7: Prospective studies of type 2 diabetes therapy and risk of dementia and Alzheimer’s disease  
Reference Study name, 
country  
Participants; 
baseline age 
Mean 
follow-
up, years 
Outcome (No. of 
cases); diagnostic 
criteria 
Antidiabetic therapy  NOS 
score 
Adjustments Adjusted RR (95% CI)  
of dementia or AD 
Ott et al, 
1999 
[52] 
Rotterdam Study, 
The Netherlands 
6370 adults; 
≥55 years 
 
2.1 Dementia (n=126); 
DSM-III-R  
Any oral antidiabetic 
medication, insulin 
therapy, no drugs  
7 Age, sex Compared with nondiabetics, the 
RRs were 2.4 (1.4–4.1) for oral 
antidiabetic therapy and 4.3 (1.7–
10.5) for insulin therapy 
Xu et al, 
2004 
[53] 
Kungsholmen 
Project, Sweden 
1301 adults; 
≥75 years 
4.3 Dementia (n=350), 
AD (n=260); DSM-
III-R, NINCDS-
ADRDA 
Any oral antidiabetic 
medication  
8 Age, sex, education, BMI, heart 
disease, stroke, blood 
pressure, antihypertensive 
drugs  
Compared with nondiabetics, the 
RRs for oral antidiabetic therapy 
were 1.7 (1.0–2.8) for dementia 
and 1.4 (0.7–2.7) for AD 
Fischer et 
al, 2008 
[35] 
Vienna 
Transdanube 
Aging Study, 
Austria 
479 adults; 
age 75 
years 
2.5 AD (n=90); DSM-IV, 
NINCDS-ADRDA 
Insulin therapy  6 None Compared with nondiabetics, the 
RRs were 1.78 (0.55–5.74) for 
insulin therapy 
Parikh et 
al, 2011 
[54] 
Veterans 
Administration, 
United States  
377 838 
diabetes 
patients; 
≥65 years 
2 Dementia (14 580); 
ICD-9-CM codes 
250.xx, 357.2, 
362.0, 366.41 
Any oral antidiabetic 
medication, insulin  
7 NS Compared with nonuse, the RRs 
were 0.94 (0.91–0.97) for oral 
antidiabetic therapy and 1.02 
(0.98–1.07) for insulin therapy  
Huang et 
al, 2014 
[55] 
National Health 
Insurance 
Research 
Database, Taiwan 
(only diabetic 
patients) 
71 433 
diabetes 
patients; 
mean age 
59 years 
5.5 
 
AD (n=346); ICD-9-
CM code 331.0 
Metformin, sulfonylureas, 
thiazolidinediones, α-
glucosidase blockers, 
nonsulfonylurea insulin 
secretagouge, insulin 
9 Age, sex, geographic area, 
urbanization, hypertension, 
hyperlipidemia, stroke, 
coronary artery disease, 
arrhythmia, heart failure, 
depression 
Compared with nonuse, the RR was 
0.92 (0.13–6.60) for 
thiazolidinediones and 1.53 
(0.98–2.39) for insulin therapy 
Heneka et 
al, 2015 
[56] 
Allgemeine 
Ortskrankenkasse
n, Germany  
145 928 
adults; ≥60 
years 
4.3 Dementia (n=13 177); 
ICD-10 codes G30, 
G31.0, G31.82, 
G23.1, F00, F01, 
F02, F03 or F05.1 
Metformin, 
thiazolidinediones  
9 None Compared with nonuse, the RR was 
0.97 (0.91–1.03) for metformin, 
0.84 (0.60–1.19) for rosiglitazone 
and 1.61 (1.46–1.77) for insulin 
therapy 
Orkaby et 
al, 2017 
[57] 
Veterans 
Administration, 
United States  
28 640 
diabetes 
patients; 
≥65 years 
5.0 Dementia (n=4906); 
ICD-9 codes 290.x, 
291.2, 294.1,294.11, 
331.x, 333.0, 333.4, 
797, 332.0, 294.8, 
046.1, 046.3 
Metformin vs. 
sulfonylureas 
9 Propensity score model with 23 
variables: race, sex, BMI, 
HbA1c, renal function, and 
comorbidities; stratified by 
age 
Compared with sulfonylureas, the 
RR for metformin use was 0.89 
(0.79–0.99) for those <75 years of 
age and 0.96 (0.87–1.05) for 
those ≥75 years of age 
Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International 
Classification of Diseases; NOS, New-Castle Ottawa Scale (quality assessment of prospective studies); RR, relative risk.
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Figure S1: Newcastle-Ottawa Scale for prospective studies: Details of how the criteria were 
applied 
Selection 
1) Representativeness of the exposed cohort  
v Star assigned if exposed cohort was truly or somewhat representative of the average 
medication users in the community (i.e., the sample was random or covered all 
individuals residing in one or a few geographical areas).  
 
2) Selection of the non-exposed cohort 
v Star assigned where non-exposed participants were drawn from the same population as 
the exposed participants. 
 
3) Ascertainment of exposure 
v Star assigned if medication use had been assessed using a structured interview or a 
prescription database. 
 
4) Demonstration that outcome of interest was not present at the start of study 
v Star assigned to studies that excluded participants with dementia and/or Alzheimer’s 
disease at baseline. 
 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
v One star assigned to studies that adjusted for age and sex (if applicable) in the 
analysis.  
v Second star assigned to studies that further adjusted for at least five other major risk 
factors (e.g., education, smoking, physical inactivity, obesity, diabetes, blood pressure 
or hypertension, cholesterol concentration or hyperlipidemia, cardiovascular diseases, 
depression, APOE-ε4) or Charlson Comorbidity Index. 
 
Outcome 
1) Assessment of outcome  
v Star assigned where an assessment for possible or probable dementia or Alzheimer’s 
disease was made in accordance with internationally accepted diagnostic criteria 
(NINCDS-ADRDA, DSM-III-R, or DSM-IV) or based on ICD codes for dementia or 
Alzheimer’s disease. 
 
2) Was follow-up long enough for outcomes to occur?   
v Star assigned where follow-up was at least 5 years. 
 
3) Adequacy of follow up of cohorts  
v Star assigned where the loss to follow-up had been estimated and reported in the 
article, and where loss was no more than 20% of those included in the final analysis. 
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Figure S2: Flow diagram of study selection process for the systematic review 
Abbreviations: AD, Alzheimer’s disease; VRF, vascular risk factor. *The number of studies 
on different treatments and interventions does not sum up to the total number because two 
articles provided results on two treatments. The PubMed search was until 1 January 2018.  
7136 non-duplicate references  
         from database search 
         !
90 articles remaining after title and 
     abstract review!
7049 not relevant (excluded based 
         on title and abstract)!
30 full-text articles excluded!
     13 duplicate studies 
       8 cross-sectional, case-control 
          or nonrandomized study 
      5 not treatment of VRF 
      4 outcome not dementia/AD 
       !
60 articles included in the review 
       8 randomized controlled trials 
           5 on hypertension treatment 
           1 on hyperlipidemia treatment 
           1 on diabetes therapy 
           1 on multiple VRFs 
     52 prospective studies*  
          20 on hypertension treatment 
          27 on hyperlipidemia treatment 
            7 on antidiabetic therapy 
7139 potentially relevant studies !
3  additional articles identified 
    from reference lists!
Identification 
Screening 
Eligibility 
Included 
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